Medicare Part D Coverage and Costs for Glucagon-Like Peptide-1 Receptor Agonists | Synapse
September 26, 2025
Medicare Part D Coverage and Costs for Glucagon-Like Peptide-1 Receptor Agonists
Key Points
This analysis reveals disparities in Medicare Part D coverage and out-of-pocket costs for GLP-1 receptor agonists.
Findings indicate significant variability in costs affecting patient access to glucagon-like peptide-1 receptor agonists.
The cross-sectional study analyzes data post-Inflation Reduction Act implementation, providing insights into coverage changes.
These insights highlight the importance of policy impacts on medication accessibility for patients with diabetes.
Abstract
This cross-sectional study examines Medicare Part D coverage and out-of-pocket costs for glucagon-like peptide-1 receptor agonists following implementation of the Inflation Reduction Act.